Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

8.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
8.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

72
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spin radical enhanced magnetocapacitance effect in intermolecular excited states.

The journal of physical chemistry. B·2013
Same author

Recent developments in stir bar sorptive extraction.

Analytical and bioanalytical chemistry·2013
Same author

Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.

ChemMedChem·2013
Same author

Magnetic polycarbonate microspheres for tumor-targeted delivery of tumor necrosis factor.

Drug delivery·2013
Same author

A study on validity of cortical alpha connectivity for schizophrenia.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2013
Same author

Myosin light chain 2-based selection of human iPSC-derived early ventricular cardiac myocytes.

Stem cell research·2013

Related Experiment Video

Updated: Apr 16, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.8K

Do thymic malignancies respond to target therapies?

Bin Hu1, Hao Rong1, Yongtao Han1

  • 1Department of Thoracic Surgery, Sichuan Cancer Hospital and Institute, Chengdu, China.

Interactive Cardiovascular and Thoracic Surgery
|March 11, 2015
PubMed
Summary

Target therapies show potential for thymic malignancies, particularly those with KIT mutations. While randomized trials are lacking, some patients with thymoma and metastatic thymic carcinoma experienced benefits, suggesting these therapies can be an option.

Keywords:
Targeted therapiesThymic malignancies

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

2.0K
Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

13.6K

Related Experiment Videos

Last Updated: Apr 16, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.8K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

2.0K
Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

13.6K

Area of Science:

  • Cardiothoracic Surgery
  • Oncology
  • Molecular Targeted Therapy

Background:

  • Thymic malignancies are rare tumors with limited treatment options.
  • The efficacy of targeted therapies in thymic malignancies remains largely unexplored due to low incidence.
  • Evidence-based review is needed to guide treatment decisions for thymic malignancies.

Purpose of the Study:

  • To evaluate the effectiveness of targeted therapies for thymic malignancies.
  • To identify specific molecular targets and agents that show promise in treating thymoma and thymic carcinoma.
  • To summarize the best available evidence on targeted therapy response in thymic malignancies.

Main Methods:

  • Systematic literature search for best evidence on targeted therapies in thymic malignancies.
  • Inclusion of 16 high-quality papers from 347 identified articles.
  • Tabulation of study characteristics, patient groups, outcomes, and results.

Main Results:

  • No randomized controlled trials were found for targeted therapies in thymic malignancies.
  • Partial responses observed with epidermal growth factor receptor tyrosine kinase inhibitors (e.g., cetuximab, erlotinib) in some cases.
  • Thymic carcinomas with KIT mutations showed benefit from targeted therapies.
  • Cixutumumab showed response in relapsed thymomas but not thymic carcinoma.
  • Belinostat demonstrated modest activity in pretreated thymoma.
  • Multitargeted kinase inhibitors (sunitinib, sorafenib) were effective in metastatic thymic carcinoma.

Conclusions:

  • Targeted therapies represent a potential treatment option for heavily pretreated thymoma patients.
  • Systematic sequencing for KIT mutations may aid in patient selection for thymic carcinoma.
  • Further research is warranted to establish the role of targeted therapies in thymic malignancies.